Vistagen Therapeutics Inc. (VTGN)
VTGN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1411685/000162828026043271/0001628280-26-043271-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-03-31.
Profile
| Field | Value |
|---|---|
| Ticker | VTGN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001411685 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.3M |
| Net income | -$69.7M |
| Operating income | -$72.1M |
| Net margin | -5491.3% |
| Operating margin | -5683.7% |
| Revenue growth | +161.1% |
| Cash | $30.8M |
| Total assets | $48.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 6.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "When substantial doubt exists under this methodology, management evaluates whether the mitigating effects of its plans sufficiently alleviate substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-13 |
| Cash and burn | $17.0M cash; operating cash flow -$15.6M a quarter. | Report 2026-06-30 |
| Shares outstanding | 46,186,049 (2026-11-10); 39,495,451 a year earlier; 27,023,038 three years earlier. | Cover page 2026-11-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-08-05 |
| Auditor | KPMG LLP, San Francisco, California, United States | PCAOB Form AP 2026-07-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-06-30 | $1.5M | -$13.0M | -$14.7M | $17.0M | $0 | $2.5M | 10-Q 2026-08-14 |
| Q4 2026 2026-03-31 | $465K | -$16.3M | -$16.2M | $30.8M | $192K | $1.3M | 10-K 2026-06-15 |
| Q3 2026 2025-12-31 | $303K | -$18.9M | -$17.6M | $47.4M | $379K | $790K | 10-Q 2026-02-12 |
| Q2 2026 2025-09-30 | $258K | -$19.4M | -$13.8M | $62.8M | $658K | $721K | 10-Q 2025-11-13 |
| Q1 2026 2025-06-30 | $244K | -$15.1M | -$18.8M | $49.0M | $933K | $646K | 10-Q 2026-08-14 |
| Q4 2025 2025-03-31 | -$15K | -$13.6M | -$10.1M | $67.1M | $0 | $486K | 10-K 2026-06-15 |
| Q3 2025 2024-12-31 | $234K | -$14.1M | -$10.3M | $74.7M | No debt tags | $698K | 10-Q 2026-02-12 |
| Q2 2025 2024-09-30 | $183K | -$13.0M | -$10.9M | $84.2M | No debt tags | $875K | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-06-17 |
| Latest annual report | 10-K | 2026-06-15 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEFA14A | 2026-07-31 |
Source: SEC EDGAR submissions feed, 913 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +12.5% |
| 1 month | -14.3% |
| 3 months | -33.3% |
| Year to date | -72.7% |
| 1 year | -95.3% |
| From 52-week high | -96.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CALC | CalciMedica Inc. | $1.19 | -1.65% | $8.2M |
| MTVA | MetaVia Inc. | $1.21 | -7.31% | $8.1M |
| PHIO | Phio Pharmaceuticals Corp. | $0.7522 | -2.44% | $9.0M |
| BFRG | Bullfrog AI Holdings Inc. | $0.4878 | -9.92% | $9.0M |
| RKTO | Rocket One Inc. | $0.3210 | +0.03% | $8.0M |
| ENSC | Ensysce Biosciences Inc. | $0.4095 | -2.13% | $8.0M |
| GDTC | CytoMed Therapeutics Limited | $0.7739 | -6.68% | $9.2M |
| LEXX | Lexaria Bioscience Corp. | $4.41 | -0.68% | $9.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier